Paul Ehrlich Institute

2020-09-08T15:30:01+00:00

Business • Health Care

Pfizer and BioNTech Covid-19 vaccine gets approved for second trial

Pfizer and BioNTech's Covid-19 vaccine BNT162b2 has been approved for its Phase II/III clinical trial by German Paul-Ehrlich-Institut. If the trials prove successful, Pfizer and BioNTech will try to seek regulatory approval as early as October.

"A large, controlled Phase III study is a crucial prerequisite to prove the safety and efficacy of a vaccine. The integration of sites in Europe, and now especially in Germany, is aimed at supporting an approval in Europe," so BioNTech CEO and co-founder Ugur Sahin.

Cookies🍪

Our website uses scripts, such as cookies, to technically provide the site ("essential scripts") and third-party website tracking technologies to provide and continually improve our services and display advertisements based on the perceived interests of users. By clicking the "Accept All" button, the website visitor agrees to the activation of all scripts. Essential cookies are also executed without the consent. The consent can be revoked or changed at any time with effect for the future. By clicking the "Reject" button, only essential cookies are used. In our data protection policy, we provide detailed information about the type and scope of data processing.

Accept All Reject